Toxicities after CAR T-cell infusion according to histopathological group in the PSM cohorts
| . | De novo LBCL . | TriNHL . | P value . |
|---|---|---|---|
| n = 85 . | n = 85 . | ||
| CRS, n (%) | |||
| Any grade | 71 (83.5) | 67 (78.8) | .4326 |
| Grade 3-4 | 4 (4.7) | 2 (2.4) | .4058 |
| Grade 5 | 0 | 0 | 1 |
| Neurotoxicity, n (%) | |||
| Any grade | 28 (32.9) | 25 (29.4) | .6194 |
| Grade 3-4 | 4 (4.7) | 5 (5.9) | .7320 |
| Grade 5 | 0 | 0 | 1 |
| Neutropenia at M1, n (%) | |||
| Any grade | 47 (55.3) | 40 (47.1) | .2828 |
| Grade 3-4 | 41 (48.2) | 37 (43.5) | .5381 |
| Grade 5 | 0 | 0 | 1 |
| Anemia at M1, n (%) | |||
| Any grade | 40 (47.1) | 41 (48.2) | .8780 |
| Grade 3-4 | 24 (28.2) | 16 (18.8) | .1480 |
| Grade 5 | 0 | 0 | 1 |
| Thrombocytopenia at M1, n (%) | |||
| Any grade | 42 (49.4) | 43 (50.6) | .8781 |
| Grade 3-4 | 31 (36.5) | 25 (29.4) | .3275 |
| Grade 5 | 0 | 0 | 1 |
| Neutropenia at M3, n (%) | |||
| Any grade | 2 (2.4) | 2 (2.4) | 1 |
| Grade 3-4 | 1 (1.2) | 2 (2.4) | .5602 |
| Grade 5 | 0 | 0 | 1 |
| Anemia at M3, n (%) | |||
| Any grade | 1 (1.2) | 1 (1.2) | 1 |
| Grade 3-4 | 1 (1.2) | 1 (1.2) | 1 |
| Grade 5 | 0 | 0 | 1 |
| Thrombocytopenia at M3, n (%) | |||
| Any grade | 1 (1.2) | 2 (2.4) | .5602 |
| Grade 3-4 | 1 (1.2) | 1 (1.2) | 1 |
| Grade 5 | 0 | 0 | 1 |
| . | De novo LBCL . | TriNHL . | P value . |
|---|---|---|---|
| n = 85 . | n = 85 . | ||
| CRS, n (%) | |||
| Any grade | 71 (83.5) | 67 (78.8) | .4326 |
| Grade 3-4 | 4 (4.7) | 2 (2.4) | .4058 |
| Grade 5 | 0 | 0 | 1 |
| Neurotoxicity, n (%) | |||
| Any grade | 28 (32.9) | 25 (29.4) | .6194 |
| Grade 3-4 | 4 (4.7) | 5 (5.9) | .7320 |
| Grade 5 | 0 | 0 | 1 |
| Neutropenia at M1, n (%) | |||
| Any grade | 47 (55.3) | 40 (47.1) | .2828 |
| Grade 3-4 | 41 (48.2) | 37 (43.5) | .5381 |
| Grade 5 | 0 | 0 | 1 |
| Anemia at M1, n (%) | |||
| Any grade | 40 (47.1) | 41 (48.2) | .8780 |
| Grade 3-4 | 24 (28.2) | 16 (18.8) | .1480 |
| Grade 5 | 0 | 0 | 1 |
| Thrombocytopenia at M1, n (%) | |||
| Any grade | 42 (49.4) | 43 (50.6) | .8781 |
| Grade 3-4 | 31 (36.5) | 25 (29.4) | .3275 |
| Grade 5 | 0 | 0 | 1 |
| Neutropenia at M3, n (%) | |||
| Any grade | 2 (2.4) | 2 (2.4) | 1 |
| Grade 3-4 | 1 (1.2) | 2 (2.4) | .5602 |
| Grade 5 | 0 | 0 | 1 |
| Anemia at M3, n (%) | |||
| Any grade | 1 (1.2) | 1 (1.2) | 1 |
| Grade 3-4 | 1 (1.2) | 1 (1.2) | 1 |
| Grade 5 | 0 | 0 | 1 |
| Thrombocytopenia at M3, n (%) | |||
| Any grade | 1 (1.2) | 2 (2.4) | .5602 |
| Grade 3-4 | 1 (1.2) | 1 (1.2) | 1 |
| Grade 5 | 0 | 0 | 1 |
Toxicities were graded according to CTCAE version 5.0 for cytopenias, and according to the consensus grading from the American Society for Transplantation and Cellular Therapy for CRS and ICANS.
CTCAE, Common Terminology Criteria for Adverse Events; M1, first month after CAR T-cell infusion; M3, third month after CAR T-cell infusion.